Toyoaki Hida
- Oncology top 0.1%
- Lung Cancer Research Studies 102
- Colorectal Cancer Treatments and Studies 59
- Cancer Immunotherapy and Biomarkers 37
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations 180
- Lung Cancer Diagnosis and Treatment 59
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 21
- Pharmacology top 0.5%
- Molecular Biology top 1%
- Cancer therapeutics and mechanisms 29
-
- Neuroendocrine Tumor Research Advances 19
- Co-authors
- Tetsuya MitsudomiYasushi YatabeTakashi TakahashiYoshitsugu HorioTakahiko SugiuraTakayuki KosakaMakoto NishioYoshitaka Sekido
- Journals
- The Journal of Experimental Medicine (1 paper)Journal of Clinical Oncology (43 papers)PLoS ONE (1 paper)
- Partner nations
- JapanUnited StatesSouth Korea
In The Last Decade
Toyoaki Hida
271 papers receiving 13.1k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Oncology 8.1k
- Pulmonary and Respiratory Medicine 8.5k
- Cancer Research 2.0k
- Pharmacology 1.2k
- Molecular Biology 4.0k
Countries citing papers authored by Toyoaki Hida
This map shows the geographic impact of Toyoaki Hida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toyoaki Hida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toyoaki Hida more than expected).
Fields of papers citing papers by Toyoaki Hida
This network shows the impact of papers produced by Toyoaki Hida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toyoaki Hida. The network helps show where Toyoaki Hida may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Toyoaki Hida, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 9 | |
| 2 | 2020 | 13 | |
| 3 | 2020 | 47 | |
| 4 | 2019 | 10 | |
| 5 | 2019 | 104 | |
| 6 | 2018 | 111 | |
| 7 | 2018 | 1 | |
| 8 | 2018 | 16 | |
| 9 | 2018 | 43 | |
| 10 | 2015 | 164 | |
| 11 | 2015 | 221 | |
| 12 | Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studybreakdown → | 2014 | 561 |
| 13 | 2011 | 181 | |
| 14 | 切除不能な第III期非小細胞肺癌(NSCLC)に対するマイトシン/ビンデシン/シスプラチン(MVP)対毎週のイリノテカン/カルボプラチン(PC)同時併用胸部放射線療法(TRT)の無作為第III相試験:WJTOG0105 | 2007 | 6 |
| 15 | The mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity of cisplatin, carboplatin and gemcitabine in human lung cancer cell lines | 2007 | 1 |
| 16 | Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent nonrandom chromosomal alteration regions including JUN amplification on 1p32 | 2007 | 3 |
| 17 | 2003 | 56 | |
| 18 | Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. | 2002 | 96 |
| 19 | 2001 | 32 | |
| 20 | 1992 | 3 |
About Toyoaki Hida
Toyoaki Hida is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 280 papers that have together received 13.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (180 papers), Lung Cancer Research Studies (102 papers), Colorectal Cancer Treatments and Studies (59 papers), Lung Cancer Diagnosis and Treatment (59 papers), Cancer Immunotherapy and Biomarkers (37 papers), Cancer therapeutics and mechanisms (29 papers), Cancer Genomics and Diagnostics (21 papers) and Neuroendocrine Tumor Research Advances (19 papers). The work is most often cited by research in Oncology (8.1k citations), Pulmonary and Respiratory Medicine (8.5k citations) and Cancer Research (2.0k citations). Toyoaki Hida has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Tetsuya Mitsudomi, Yasushi Yatabe, Takashi Takahashi, Yoshitsugu Horio, Takahiko Sugiura, Takayuki Kosaka, Makoto Nishio, Yoshitaka Sekido, Junichi Shimizu and Takashi Seto. Their work appears in journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.